
Ono Pharmaceutical Co Ltd (4528) - Financial and Strategic SWOT Analysis Review
Description
Ono Pharmaceutical Co Ltd (4528) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is an immuno-oncology company that provides research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. The company's product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma, and allergic rhinitis, among others for the treatment of cancer. The company also offers products in various formulations such as capsules, patches, dry syrup, tablets, injections, and intravenous infusions. Ono Pharmaceutical has manufacturing facilities including Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
Ono Pharmaceutical Co Ltd Key Recent Developments
Sep 17,2025: Deciphera Receives European Commission Approval for Vimseltinib in TGCT Treatment
Aug 01,2025: Notice Concerning the Establishment of Ono Global Reinsurance As An Overseas Subsidiary (Specified Subsidiary)
Aug 01,2025: Ono Pharmaceutical Co. Ltd. Reports Retreat In Q1 Bottom Line
May 08,2025: Ono Pharmaceutical Reports Results for Fiscal Year Ended March 31, 2025
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is an immuno-oncology company that provides research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. The company's product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma, and allergic rhinitis, among others for the treatment of cancer. The company also offers products in various formulations such as capsules, patches, dry syrup, tablets, injections, and intravenous infusions. Ono Pharmaceutical has manufacturing facilities including Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
Ono Pharmaceutical Co Ltd Key Recent Developments
Sep 17,2025: Deciphera Receives European Commission Approval for Vimseltinib in TGCT Treatment
Aug 01,2025: Notice Concerning the Establishment of Ono Global Reinsurance As An Overseas Subsidiary (Specified Subsidiary)
Aug 01,2025: Ono Pharmaceutical Co. Ltd. Reports Retreat In Q1 Bottom Line
May 08,2025: Ono Pharmaceutical Reports Results for Fiscal Year Ended March 31, 2025
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
63 Pages
- Section 1 - About the Company
- Ono Pharmaceutical Co Ltd - Key Facts
- Ono Pharmaceutical Co Ltd - Key Employees
- Ono Pharmaceutical Co Ltd - Key Employee Biographies
- Ono Pharmaceutical Co Ltd - Major Products and Services
- Ono Pharmaceutical Co Ltd - History
- Ono Pharmaceutical Co Ltd - Company Statement
- Ono Pharmaceutical Co Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Ono Pharmaceutical Co Ltd - Business Description
- Geographical Segment: Americas
- Performance
- Geographical Segment: Asia
- Performance
- Geographical Segment: Europe
- Performance
- Geographical Segment: Japan
- Performance
- R&D Overview
- Ono Pharmaceutical Co Ltd - Corporate Strategy
- Ono Pharmaceutical Co Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Ono Pharmaceutical Co Ltd - Strengths
- Ono Pharmaceutical Co Ltd - Weaknesses
- Ono Pharmaceutical Co Ltd - Opportunities
- Ono Pharmaceutical Co Ltd - Threats
- Ono Pharmaceutical Co Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Ono Pharmaceutical Co Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Sep 17, 2025: Deciphera Receives European Commission Approval for Vimseltinib in TGCT Treatment
- Aug 01, 2025: Notice Concerning the Establishment of Ono Global Reinsurance As An Overseas Subsidiary (Specified Subsidiary)
- Aug 01, 2025: Ono Pharmaceutical Co. Ltd. Reports Retreat In Q1 Bottom Line
- May 08, 2025: Ono Pharmaceutical Reports Results for Fiscal Year Ended March 31, 2025
- Apr 21, 2025: Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
- Apr 07, 2025: Ono Pharmaceutical Makes Changes of Board of Directors and Corporate Officers
- Apr 07, 2025: Ono Pharmaceutical Announces Changes of Board of Directors and Corporate Officers
- Feb 28, 2025: Ono Pharmaceutical Announces Reorganization of its US and Europe Operations
- Oct 31, 2024: Revisions of Consolidated Financial Forecasts and Introduction of Core Basis in Financial Results
- Oct 31, 2024: Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2025 (IFRS)
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Ono Pharmaceutical Co Ltd, Key Facts
- Ono Pharmaceutical Co Ltd, Key Employees
- Ono Pharmaceutical Co Ltd, Key Employee Biographies
- Ono Pharmaceutical Co Ltd, Major Products and Services
- Ono Pharmaceutical Co Ltd, History
- Ono Pharmaceutical Co Ltd, Other Locations
- Ono Pharmaceutical Co Ltd, Subsidiaries
- Ono Pharmaceutical Co Ltd, Key Competitors
- Ono Pharmaceutical Co Ltd, Ratios based on current share price
- Ono Pharmaceutical Co Ltd, Annual Ratios
- Ono Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
- Ono Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
- Ono Pharmaceutical Co Ltd, Interim Ratios
- Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Ono Pharmaceutical Co Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Ono Pharmaceutical Co Ltd, Performance Chart (2021 - 2025)
- Ono Pharmaceutical Co Ltd, Ratio Charts
- Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.